Offer end-to-end workflow from library prep through sequencing

Twist to be sole provider of new Trinity™ library prep and target enrichment kits for Element AVITI™ sequencer

Joint commercial activities to expand customer access to new NGS tools

SOUTH SAN FRANCISCO, Calif. & SAN DIEGO--(BUSINESS WIRE)--May 22, 2025-- Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Element Biosciences, Inc., a company democratizing access to advanced life science solutions, today announced an expanded collaboration to enable Element’s AVITI systems and Trinity flowcells with additional Twist library preparation and target enrichment workflows.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250522262675/en/

“This collaboration builds on our existing relationship with Element, which has yielded Twist's on-market Element-native kit and 1-hour fast hybridization Trinity solution. Twist will have exclusive access to develop additional library prep and target enrichment workflows compatible with Element’s Trinity sequencing technology, giving Element customers access to the uniformity, consistency and quality provided by our NGS tools,” said Emily M. Leproust, CEO and co-founder of Twist Bioscience. “This will further advance Twist and Element's shared goal to radically streamline hybrid capture processes both off and on the sequencer. With the expansion of our co-development and commercial efforts, we will be able to further serve critical markets such as agbio, population genomics and clinical research. Adapting our broadly compatible and innovative NGS workflows to work on Element’s sequencing platform demonstrates the broad applicability and versatility of our NGS products and enables customers flexibility to choose the system that best meets their needs without sacrificing uniformity or quality delivered through the Twist portfolio.”

"By uniting our revolutionary Trinity workflow for targeted sequencing with Twist's superior library preparation capabilities, we're creating an integrated solution that further catalyzes access to premium life science tools and accelerates scientific discovery across every field,” said Molly He, CEO and co-founder of Element Biosciences. “Our partnership with Twist reflects both our companies' drive to remove barriers that have constrained innovation in this space for far too long."

The collaboration between Twist and Element will enable researchers to access end-to-end workflows from library prep through sequencing on Element’s AVITI platform, which offers high-quality sequencing and flexibility. Under the collaboration, Twist will be the exclusive partner of these new library prep and target enrichment workflows, expanding the existing Trinity offerings beyond exome sequencing and delivering industry-leading performance across key NGS applications. Twist and Element will engage in joint commercial and promotional activities to improve customer access to these innovative solutions.

About Element Biosciences, Inc.

Element Biosciences is a life science company democratizing access to advanced biological tools, driving impactful discoveries to benefit humanity. Through innovating every fundamental element of a biological assay system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries. To learn more about Element, please visit www.elementbiosciences.com and follow us on LinkedIn, X (Twitter), and Facebook.

About Twist Bioscience Corporation

At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and defense, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts.

Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. For more information about our products and services, please visit www.twistbioscience.com.

Follow us on LinkedIn | X | YouTube | Instagram | Bluesky

Twist Bioscience Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; ability to obtain financing when necessary; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist is developing obsolete or non-competitive; ability to expand DNA synthesis manufacturing capacity; dependence on one supplier for a critical component; dependence on key personnel; additional regulations that could increase Twist’s costs and delay commercialization efforts; changes in U.S. trade policies and other trade actions that could result in increased costs and supply chain disruptions; and the ability to maintain and enforce intellectual property protection. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist’s business in general, see Twist’s risk factors set forth in Twist’s Annual Report on Form 10-K for the year ended September 30, 2024 filed with the Securities and Exchange Commission (SEC) on November 18, 2024 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250522262675/en/

FOR TWIST:

For Investors:
Angela Bitting
SVP, Corporate Affairs
925-202-6211
abitting@twistbioscience.com

For Media:
Amanda Houlihan
Communications Manager
774-265-5334
ahoulihan@twistbioscience.com

FOR ELEMENT:

Michael Sullivan
Corporate Communications Manager
503-799-7520
Media@elembio.com

Source: Twist Bioscience Corporation